Startup India Government of India
Mericana Pharmaceuticals Private Limited - pharma in Indore, Madhya Pradesh, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹3.65 Cr
▼ 43% YoY
Net profit · FY 2025
₹3.97 Lakh
Net margin 1.1%
EBITDA · FY 2025
₹11.59 Lakh
EBITDA margin 3.2%
Authorised capital
₹10 Lakh
Registered with MCA
Paid-up capital
₹1 Lakh
Issued & subscribed
Open charges
₹1 Cr
Secured borrowings
Company age
7 yrs
Est. 2019
Directors on board
4
As per MCA filings
About Mericana Pharmaceuticals Private Limited
Data last updated:
Mericana Pharmaceuticals Private Limited is a private limited company based in Indore, Madhya Pradesh, India, recognised as a startup by DPIIT. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 29 March 2019 and has been in existence for over 7 years.
The company is registered with the Registrar of Companies (ROC), Gwalior, under CIN U33110MP2019PTC048220. Its GSTIN is 23AAMCM5616P1ZZ (Madhya Pradesh).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors including Suresh Kshirsagar and Gaurav Kshirsagar.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at C/O – Suresh Kshirsagar 556 Usha Nagar Extension, Indore, Madhya Pradesh, India – 452009.
As per the financials filed for FY 2025, the company reported a revenue of ₹3.65 Cr, a decline of 43% compared to the previous year. For the same year it recorded a net profit of ₹3.97 Lakh (net margin 1.1%) and EBITDA of ₹11.59 Lakh (EBITDA margin 3.2%). Revenue has grown at a compounded annual rate (CAGR) of 8% over three years and 3% over five years.
The company is associated with 1 brand: Mericanapharma. As per MCA filings, the company has open charges of ₹1 Cr on record.
Mericana Pharmaceuticals Private Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-MP-23-0042993). For more details, the company can be reached via its website mericanapharma.com.
Company Details of Mericana Pharmaceuticals Private Limited
CIN U33110MP2019PTC048220
Registration Number 048220
Incorporation Date 29 March 2019
ROC Gwalior
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2023
Date of Balance Sheet 31 March 2023
DPIIT Recognition Recognised Startup
MSME Classification Micro
Udyam Registration UDYAM-MP-23-0042993
Recognitions & Rankings of Mericana Pharmaceuticals
MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-MP-23-0042993
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social MediaLocked
- Registered AddressC/O – Suresh Kshirsagar 556 Usha Nagar Extension, Indore, Madhya Pradesh, India – 452009
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Mericana Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals operates one associated brand: Mericanapharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers affordable pharmaceutical products and services for global community. | mericanapharma.com |
Business Activity of Mericana Pharmaceuticals Private Limited
The main business activity of Mericana Pharmaceuticals is trade. In detail, this covers wholesale trading.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Mericana Pharmaceuticals Private Limited FY 2023 filings available
Mericana Pharmaceuticals Private Limited reported revenue of ₹3.65 Cr (down 43% YoY) for FY 2025.
Revenue · FY 2025
₹3.65 Cr ▼ 43%
Net profit · FY 2025
₹3.97 Lakh margin 1.1%
EBITDA · FY 2025
₹11.59 Lakh margin 3.2%
Compounded Annual Growth Rate (CAGR) of Mericana Pharmaceuticals Private Limited
Revenue CAGR growth
1 year
▼ 43%
3 years · compounded
▼ 8%
5 years · compounded
▲ 3%
EBITDA CAGR growth
1 year
▼ 82%
3 years · compounded
▼ 48%
5 years · compounded
▼ 30%
Revenue fell 43% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 3%. EBITDA fell 82% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Mericana Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹11.59 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹3.97 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Mericana Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 3.2% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.1% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Mericana Pharmaceuticals are in the company report.
Premium access
Financial statements from FY 2019
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals has 4 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Suresh Kshirsagar | Director | 29 Mar 2019 | 7 Years 6 Months | Current |
| Gaurav Kshirsagar Also directs: Welltek Lifesciences Private Limited | Director | 24 Sep 2020 | 6 Years 0 Months | Current |
| Priyesh Kumar Sinha Also directs: Welltek Lifesciences Private Limited | Director | 24 Sep 2020 | 6 Years 0 Months | Current |
| Madan Kumar Sinha | Director | 29 Mar 2019 | 7 Years 6 Months | Current |
Peer Comparison of Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Bionovics Pharmaceuticals Private Limited | ₹3.66 Cr (FY 2025) | •••• | •••• | 26.0% | •••• | Jabalpur, Madhya Pradesh, India |
| Ravi Plant Biotechnologies Limited | ₹3.66 Cr (FY 2025) | •••• | •••• | 21.0% | •••• | Panchmahals, Gujarat, India |
| Invision Pharma Limited | ₹3.66 Cr (FY 2024) | •••• | •••• | 29.0% | •••• | Bengaluru, Karnataka, India |
| Sarcoma Remedies Private Limited | ₹3.65 Cr (FY 2025) | •••• | •••• | -10.0% | •••• | Manimajra, Chandigarh, India |
| All-Cure Pharma Private Limited | ₹3.65 Cr (FY 2024) | •••• | •••• | 5.0% | •••• | New Delhi, Delhi, India |
| Mericana Pharmaceuticals Private Limited this company | ₹3.65 Cr (FY 2025) | •••• | •••• | -43.0% | •••• | Indore, Madhya Pradesh, India |
| Arya Aushadhi Private Limited | ₹3.65 Cr (FY 2025) | •••• | •••• | 24.0% | •••• | Mumbai, Maharashtra, India |
| Lord Venky Pharma Pvt Ltd | ₹3.65 Cr (FY 2025) | •••• | •••• | -9.0% | •••• | Yanam, U.T Of, Pondicherry, India |
| Celera Healthcare Private Limited | ₹3.64 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Lucknow, Uttar Pradesh, India |
| Uniplus Biotech Private Limited | ₹3.64 Cr (FY 2024) | •••• | •••• | -3.0% | •••• | Hapur, Uttar Pradesh, India |
| Stanley Medicare Private Limited | ₹3.63 Cr (FY 2025) | •••• | •••• | 19.0% | •••• | New Delhi, Delhi, India |
Peers are the five companies nearest above and the five nearest below Mericana Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals Private Limited is audited by J K C & COMPANY for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| J K C & COMPANY | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Mericana Pharmaceuticals Private Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Mericana Pharmaceuticals Private Limited
Open charges
₹1 Cr
Satisfied charges
None
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Dec 2024 | Hdfc Bank Limited | ₹1 Cr | Open |
Total charge records: 1 View all charges
Employees and EPFO Compliance at Mericana Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Mericana Pharmaceuticals.
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals Private Limited has 6 board changes on record since 2019: 4 appointments and 2 cessations. The latest: Gaurav Kshirsagar ceased to be Additional Director on 30 Dec 2020.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 100.00 Lakh with Charge ID 101031429 was registered on 23 Dec 2024.
AGM
Mericana Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records.
Filing
Mericana Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Gwalior.
Ceased
Gaurav Kshirsagar ceased to be Additional Director.
Ceased
Priyesh Kumar Sinha ceased to be Additional Director.
Appointed
Gaurav Kshirsagar was appointed as Director.
Appointed
Priyesh Kumar Sinha was appointed as Director.
Appointed
Madan Kumar Sinha was appointed as Director.
Appointed
Suresh Kshirsagar was appointed as Director.
Incorporation
29 Mar 2019
Mericana Pharmaceuticals Private Limited was registered on 29 Mar 2019 with Roc Gwalior & aged 7 years 6 months as per MCA records.
Credit Ratings, Litigation & Regulatory Alerts for Mericana Pharmaceuticals Private Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Mericana Pharmaceuticals Private Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Mericana Pharmaceuticals Private Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals has 1 GST registration: 1 active.
Total GSTINs
1
Active
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 23AAMCM5616P1ZZ | Madhya Pradesh | Active | 14 May 2019 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Mericana Pharmaceuticals Private Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mericana Pharmaceuticals Private Limited
Mericana Pharmaceuticals is an active private limited company based in Indore, Madhya Pradesh, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 29 March 2019 (7+ years old) and is registered under CIN U33110MP2019PTC048220.
Mericana Pharmaceuticals reported revenue of ₹3.65 Cr for FY 2025 (down 43% YoY).
Mericana Pharmaceuticals has 4 current directors:
- Suresh Kshirsagar - Director
- Gaurav Kshirsagar - Director
- Priyesh Kumar Sinha - Director
- Madan Kumar Sinha - Director
Mericana Pharmaceuticals reported a net profit of ₹3.97 Lakh (net margin 1.1%) and EBITDA of ₹11.59 Lakh (EBITDA margin 3.2%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Mericana Pharmaceuticals is -8% over three years and 3% over five years. In the latest year (FY 2025) revenue fell 43%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Mericana Pharmaceuticals is 23AAMCM5616P1ZZ, registered in Madhya Pradesh.
The CIN (Corporate Identification Number) of Mericana Pharmaceuticals is U33110MP2019PTC048220. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Mericana Pharmaceuticals was incorporated on 29 March 2019, making it 7+ years old. It is registered with the Registrar of Companies, Gwalior.
The peers of Mericana Pharmaceuticals by revenue are Bionovics Pharmaceuticals Private Limited, Ravi Plant Biotechnologies Limited, Invision Pharma Limited, Sarcoma Remedies Private Limited, All-Cure Pharma Private Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Gaurav Kshirsagar ceased to be Additional Director on 30 Dec 2020. Priyesh Kumar Sinha ceased to be Additional Director on 30 Dec 2020. Gaurav Kshirsagar was appointed as Director on 24 Sep 2020. Mericana Pharmaceuticals has 6 board changes on record in total.
Yes, Mericana Pharmaceuticals is recognised as a startup by the Department for Promotion of Industry and Internal Trade (DPIIT).